You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

 

Online download statistics by month:

Online download statistics by month: March 2021 to October 2021

AbstractFullPdf
Mar 2021594592304
Apr 2021378378133
May 202123223278
Jun 202120120163
Jul 202117917960
Aug 202116316350
Sep 202114314366
Oct 202119019069
Total20802078823